Amarin Corp Plc (AMRN)

[caddiedad]

A very interesting review of Mitigate, due 2 weeks from today.
From “D” 24 minutes ago on Yahoo.
MITIGATE is not about therapy. It's about mitigating the effects of COVID after contracting the disease, (important to note those in the trial have been mostly vaccinated and boosted). This is for patients with heart disease, not just the REDUCE-IT population, a population 5 times the size of REDUCE-IT; no statin or triglyceride requirements. And not just to reduce the severity of symptoms from COVID, but also to prevent cardiovascular events stemming from complications of the disease. And not just COVID, but all respiratory tract diseases. Since new variants will almost certainly evade vaccines and natural immunity, protecting ones heart while also mitigating COVID in the future is incredibly appealing. One other point here. There is a lot of confusion over how many patients are actually in the study's treatment arm, 1500 to 3900? Knowing KP, they likely decided to add generic V patients in separate arms as they want to make sure prescribing the generic is cost effective too. MITIGATE might be the undoing of the generics in the US if those arms fail while brand succeeds, but that's just conjecture. April 3rd could be enormous.